AstraZeneca PLC Ordinary Shares (AZN)
Stock · NYSE · Health Care
$165.42as of 10/16/2026
Price chart
Active signals
AZN Signal Track Record
How signals performed across all stocks →What AZN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| 200-Day Moving Average TouchActive now | 23 | -0.7% | 43% | June 23, 2026 |
| Volume Spike | 23 | -0.3% | 48% | September 8, 2026 |
| Bollinger Band Breakout | 19 | +2.7% | 53% | June 26, 2026 |
| Bollinger Band Breakdown | 18 | +0.3% | 50% | August 4, 2026 |
| Any 20-session window (baseline) | +0.7% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 96,100
- Website
- www.astrazeneca.com/
Fundamentals
- 1-day range
- $164.37$167.18
- Market cap
- $249.78B
- P/E (trailing)
- 24.19
- P/E (forward)
- 14.58
- EPS (trailing)
- $6.69
- Dividend yield
- 2.30%
- Beta
- 1.27
- Avg. volume
- 3.36M
- Ex-dividend date
- August 7, 2026
- Dividend pay date
- September 8, 2026
Forecasts
12 analyst ratings
AstraZeneca PLC Ordinary Shares Competitors
Chosen by industry and closest market cap.
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- AstraZeneca (LSE:AZN) Puts AI Into Biologics Labs With New Discovery Tie UpYahoo · 10/10/2026
- Cancer Stocks to Consider as Oncology Innovation AcceleratesYahoo · 10/9/2026
- Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York TimesBenzinga · 10/9/2026
- Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerYahoo · 10/8/2026
- AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?Yahoo · 10/8/2026
- Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAHBenzinga · 10/8/2026
- Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsYahoo · 10/8/2026
- SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technologybenzinga · 10/8/2026
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyYahoo · 10/8/2026
Insider Activity
Insider Actions →- Sharma Mani · October 6, 2026 · Grant2 @ $159.8
- Sharma Mani · September 8, 2026 · Grant1 @ $162.6
- Sharma Mani · August 8, 2026 · Buy20 @ $160.57
- Sharma Mani · August 6, 2026 · Grant2 @ $163.34
- Sharma Mani · July 6, 2026 · Grant2 @ $190.43
- Sharma Mani · June 8, 2026 · Grant1 @ $179.75
- Sharma Mani · May 20, 2026 · Sale11.9K @ $185.78
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AZN Announces AI Drug Discovery Partnership and Trial Outlook
AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.
AZN Announces AI Drug Discovery Partnership and Trial Outlook. AstraZeneca disclosed a new partnership with insitro to use artificial intelligence for drug discovery in MASH and cardiomyopathies. The collaboration aims to accelerate early‑stage research and could expand the company's pipeline. Around the same time, RBC reaffirmed an outperform rating ahead of the AVANZAR lung‑cancer trial, while the stock outperformed the broader market in recent trading. These developments add focus to both innovative research and upcoming clinical data.